P. Fleck

6.0k citations

38 papers · 4.7k indexed · 2 hit papers · h-index 27

Impact in

Endocrinology, Diabetes and Metabolism top 0.1%
- Diabetes Treatment and Management
- Diabetes Management and Research
Pharmacology top 1%
- Pharmacology and Obesity Treatment

Papers in ⓘ

Endocrinology, Diabetes and Metabolism 34
- Diabetes Treatment and Management 33
- Diabetes Management and Research 11
Molecular Biology 13
- Metabolism, Diabetes, and Cancer 12

Co-authors: Craig Wilson (14 shared papers)Qais Mekki (13 shared papers)William B. White (9 shared papers)Christopher P. Cannon (8 shared papers)Faı̈ez Zannad (7 shared papers)William C. Cushman (8 shared papers)Cyrus R. Mehta (8 shared papers)George L. Bakris (7 shared papers)
Journals: Diabetes Obesity and Metabolism (8 papers)Journal of the American College of Cardiology (3 papers)Diabetes Care (3 papers)Clinical Therapeutics (2 papers)Diabetes and Vascular Disease Research (1 paper)
Partner nations: United States United Kingdom France

In The Last Decade

P. Fleck

37 papers receiving 4.5k citations

Hit Papers

align trajectories log scale

Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial 2015 · 551 citations

Peers

Countries citing papers authored by P. Fleck

Since Specialization

Citations

This map shows the geographic impact of P. Fleck's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by P. Fleck with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites P. Fleck more than expected).

Fields of papers citing papers by P. Fleck

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by P. Fleck. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by P. Fleck. The network helps show where P. Fleck may publish in the future.

Co-authors

The 25 scholars most cited alongside P. Fleck, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with P. Fleck Line = papers co-authored together P. Fleck links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 38 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes New England Journal of Medicine ·William B. White, Christopher P. Cannon, Simon Heller, Steven E. Nissen, Richard M. Bergenstal, George L. Bakris, Alfonso T. Perez, P. Fleck, Cyrus R. Mehta, Stuart Kupfer, Craig Wilson, William C. Cushman, Faı̈ez Zannad Hit paper breakdown →	2013	1857
2	Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial The Lancet ·Faı̈ez Zannad, Christopher P. Cannon, William C. Cushman, George L. Bakris, Venu Menon, Alfonso T. Perez, P. Fleck, Cyrus R. Mehta, Stuart Kupfer, Craig Wilson, Hung‐Ming Lam, William B. White Hit paper breakdown →	2015	551
3	Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Alogliptin in Patients With Type 2 Diabetes and Inadequate Glycemic Control Diabetes Care ·Ralph A. DeFronzo, P. Fleck, Craig Wilson, Qais Mekki, (unknown)	2008	193
4	Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study International Journal of Clinical Practice ·Michael A. Nauck, Graham C. Ellis, P. Fleck, Carol Wilson, Qais Mekki, (unknown)	2008	184
5	Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA _1c without causing weight gain or increased hypoglycaemia Diabetes Obesity and Metabolism ·Julio Rosenstock, Marc Rendell, Jorge Luiz Gross, P. Fleck, Carol Wilson, Qais Mekki	2009	170
6	Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy Diabetes Obesity and Metabolism ·Richard E. Pratley, Mark Kipnes, P. Fleck, Candy Wilson, Qais Mekki, (unknown)	2008	143
7	EXamination of CArdiovascular OutcoMes with AlogliptIN versus Standard of CarE in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome (EXAMINE) American Heart Journal ·William B. White, George L. Bakris, Richard M. Bergenstal, Christopher P. Cannon, William C. Cushman, P. Fleck, Simon Heller, Cyrus R. Mehta, Steven E. Nissen, Alfonso Pérez, Craig Wilson, Faı̈ez Zannad	2011	128
8	Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: A randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes Clinical Therapeutics ·Paul S. Covington, Ronald Christopher, Miles P. Davenport, P. Fleck, Qais Mekki, Elisabeth R. Wann, Aziz Karim	2008	118
9	Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study Current Medical Research and Opinion ·Richard E. Pratley, Jane E.B. Reusch, P. Fleck, Craig Wilson, Qais Mekki, (unknown)	2009	117
10	Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects Clinical Therapeutics ·Ronald Christopher, Paul S. Covington, Miles P. Davenport, P. Fleck, Qais Mekki, Elisabeth R. Wann, Aziz Karim	2008	106
11	Cardiovascular safety of the dipetidyl peptidase‐4 inhibitor alogliptin in type 2 diabetes mellitus Diabetes Obesity and Metabolism ·William B. White, Richard E. Pratley, P. Fleck, Melvin Munsaka, Michie Hisada, Candy Wilson, Venu Menon	2013	105
12	Initial Combination Therapy With Alogliptin and Pioglitazone in Drug-Naïve Patients With Type 2 Diabetes Diabetes Care ·Julio Rosenstock, Silvio E. Inzucchi, Jochen Seufert, P. Fleck, Craig Wilson, Qais Mekki	2010	102
13	Efficacy and Tolerability of the DPP-4 Inhibitor Alogliptin Combined with Pioglitazone, in Metformin-Treated Patients with Type 2 Diabetes The Journal of Clinical Endocrinology & Metabolism ·Ralph A. DeFronzo, Charles Burant, P. Fleck, Candy Wilson, Qais Mekki, Richard E. Pratley	2012	87
14	Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone: a 52‐week, randomized, double‐blind, active‐controlled, parallel‐group study Diabetes Obesity and Metabolism ·Emanuele Bosi, Graham C. Ellis, Carol Wilson, P. Fleck	2011	77
15	Lowering of postprandial lipids in individuals with type 2 diabetes treated with alogliptin and/or pioglitazone: a randomised double-blind placebo-controlled study Diabetologia ·Björn Eliasson, Diane L. Möller-Goede, Katarina Eeg‐Olofsson, Candy Wilson, Jan Cederholm, P. Fleck, M. Diamant, Marja‐Riitta Taskinen, Ulf Smith	2012	75
16	Alogliptin versus glipizide monotherapy in elderly type 2 diabetes mellitus patients with mild hyperglycaemia: a prospective, double‐blind, randomized, 1‐year study Diabetes Obesity and Metabolism ·Julio Rosenstock, Candy Wilson, P. Fleck	2013	72
17	Efficacy and safety of glucagon‐like peptide‐1/glucagon receptor co‐agonist JNJ‐64565111 in individuals with obesity without type 2 diabetes mellitus: A randomized dose‐ranging study Clinical Obesity ·Maria Alba, Jaqueline Yee, Mary Ellen Frustaci, Mahesh N. Samtani, P. Fleck	2021	68
18	Alogliptin Use in Elderly People: A Pooled Analysis from Phase 2 and 3 Studies Journal of the American Geriatrics Society ·Richard E. Pratley, Thérèse McCall, P. Fleck, Craig Wilson, Qais Mekki	2009	64
19	Durability of the efficacy and safety of alogliptin compared with glipizide in type 2 diabetes mellitus: a 2‐year study Diabetes Obesity and Metabolism ·Stefano Del Prato, R. Camisasca, Candy Wilson, P. Fleck	2014	64
20	Migraine and migrainous stroke Neurology ·JF Rothrock, James North, K P Madden, Patrick Lyden, P. Fleck, Howard C. Dittrich	1993	56

About P. Fleck

P. Fleck is a scholar working on Endocrinology, Diabetes and Metabolism, Molecular Biology, Surgery, Oncology and Cardiology and Cardiovascular Medicine, having authored 38 papers that have together received 4.7k indexed citations. Recurring topics across this work include Diabetes Treatment and Management (33 papers), Metabolism, Diabetes, and Cancer (12 papers), Diabetes Management and Research (11 papers), Pancreatic function and diabetes (10 papers), Peptidase Inhibition and Analysis (7 papers), Heart Failure Treatment and Management (3 papers), Renal Transplantation Outcomes and Treatments (3 papers) and Cardiovascular Function and Risk Factors (3 papers). The work is most often cited by research in Endocrinology, Diabetes and Metabolism (4.3k citations), Pharmacology (661 citations), Oncology (1.0k citations), Surgery (1.5k citations) and Cardiology and Cardiovascular Medicine (699 citations). P. Fleck has collaborated with scholars based in United States, United Kingdom and France. Frequent co-authors include Craig Wilson, Qais Mekki, William B. White, Christopher P. Cannon, Faı̈ez Zannad, William C. Cushman, Cyrus R. Mehta, George L. Bakris, Stuart Kupfer and Alfonso T. Perez. Their work appears in journals such as Diabetes Obesity and Metabolism, Journal of the American College of Cardiology, Diabetes Care, Clinical Therapeutics and Diabetes and Vascular Disease Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact